The US Food and Drug Administration (FDA) has extended Regenxbio’s review timeline of the Biologics License Application (BLA) ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

US FDA extends review timeline of Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II: Rockville, Maryland Wednesday, August 20, 2025, 18:00 Hrs [IST] ...

WuXi has a wide range of technical platforms for state-of-the-art biologic innovations, including the bispecific and multispecific antibodies platform under WuXiBody, the Chinese hamster ovary ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates ...

CG Oncology Inc. (NASDAQ:CGON) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 16, ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Pharmaceuticals announced that the Food and Drug Administration has extended the target action dates to Q4 of 2025 for two Eylea ...

RemeGen and Santen ink exclusive licensing agreement for ophthalmic innovative drug RC28-E in Greater China and Asian countries: Yantai, China Wednesday, August 20, 2025, 11:00 Hr ...

Clinical progress, regulatory momentum, and consolidation are converging to define what could be one of the most transformative periods in biotech history. Medicus Pharma Ltd. (NASDAQ: MDCX) is an ...

Omeros Corporation ( NASDAQ: OMER) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET ...